Pharyngitis/tonsillitis caused by Streptococcus pyogenes
Acute bacterial otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis (including beta-Iactamase-producing strains) or Streptococcus pyogenes.
Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae, or Haemophilus influenzae (beta-lactamase-producing strains only)
Lower respiratory tract infections including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Klebsiella spp., Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus pyogenes, Escherichia coli.
Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by Streptococcus pneumoniae, Haemophilus Influenzae (beta-Iactamase negative strains), or Haemophilus parainfluenzae (beta-Iactamase negative strains).
Skin and Skin Structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus pyogenes, Escherichia coli, Klebsiella spp., and Enterobacter spp.
Urinary tract infections caused by Escherichia coli or Klebsiella pneumoniae.
Bone and Joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains).
Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase and non-penicillinase producing strains) in both males and females.
Early Lyme disease (erythema migrains) caused by Borrelia burgdorferi.
Septicemia caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp.
Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis and Staphylococcus aureus (penicillinase and non-penicillinase producing strains).
Surgical Prophylaxis: Prophylaxis against infections in abdominal, pelvic, orthopedic, cardiac, pulmonary, esophageal and vascular surgery where there is increased risk for infection.

Adolescents & adults (13 years, above)  
Pharyngitis or Tonsillitis      250 mg twice daily    5-10 days
Acute bacterial maxillary sinusitis     250 mg twice daily    10 days
Acute bacterial exacerbation of chronic bronchitis   250-500 mg twice daily    10 days
Secondary bacterial infections of acute bronchitis   250-500 mg twice daily    5-10 days
Uncomplicated skin & skin-structure infections    250-500 mg twice daily    10 days
Uncomplicated urinary tract infection    125-250 mg twice daily    7-10 days
Uncomplicated gonorrhoea     1000 mg single dose    ---
Lyme disease 500 mg twice daily   20 days
Paediatric patients (Up to 12 years)
(Who can swallow tablets whole)  
Pharyngitis or Tonsilitis      125mg twice daily 5-10 days Acute otitis media       250 mg twice daily    10 days
Acute bacterial maxillary sinusitis     250 mg twice daily    10 days
Suspension
(Must be administered with food. Shake the bottle well before each use)   
Paediatric patients (3 months to 12 years)
Pharyngitis or Tonsilitis      20 mg/kg/day in two divided doses   5-10 days
Acute otitis media       30 mg/kg/day in two divided doses   10 days
Acute bacterial maxillary sinusitis     30 mg/kg/day in two divided doses   10 days
Sequential therapy in adults
Pneumonia: 500 mg twice daily (oral) for 7-10 days.
Acute exacerbations of chronic bronchitis: 750 mg twice daily for 2-3 days, followed by 500 mg twice daily (oral) for 5-10 days. Duration of oral therapy is determined by the severity of the infection and the clinical status of the patient.

Concomitant administration of probenecid with Cefuroxime increases the area under the serum concentration versus time curve by 50%. Drug that reduces gastric acidity may result in a lower bioavailability of Cefuroxime and tend to cancel the effect of postprandial absorption.

Patients with known allergy to cephalosporins and pseudomembranous colitis are contraindicated.

Generally Cefuroxime is well tolerated. However, a few side effects like nausea, vomiting, diarrhoea, abdominal discomfort or pain may occur. As with other broad-spectrum antibiotics, prolonged administration of Cefuroxime may result in overgrowth of nonsusceptible microorganisms. Rarely (<0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear.

Cefuroxime has been safely used in later pregnancy to treat urinary and other infections.
Nursing mothers: Cefuroxime is excreted into the breast milk in small quantities. However, the possibility of sensitizing the infant should be kept in mind.

Cefuroxime should be given with care to patients receiving concurrent treatment with potent diuretics & who have history of colitis.

Signs and symptoms: Overdosage of Cefuroxime can cause cerebral irritation leading to convulsions.
Management: Serum levels of Cefuroxime can be reduced by haemodialysis and peritoneal dialysis.

Cefuroxime tablet, powder for suspension should be kept in a cool (15oC- 30oC) and dry place and protected from light.